Company intelligence / Profile preview

ANR

San Francisco, California, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

ANR Therapeutics is a biotechnology company focused on developing innovative treatments for nicotine addiction and smoking cessation. The company utilizes a proprietary platform to design small molecule modulators that target specific nicotinic acetylcholine receptors in the brain. By addressing the underlying neurobiology of addiction, ANR Therapeutics aims to provide more effective and safer alternatives to current smoking cessation therapies. Their lead programs are currently in the pre-clinical stage, with a focus on optimizing drug candidates for future clinical trials.

Therapeutic areas: Psychiatry
Modalities: Small moleculeRNA therapy
Industry: Biotech

Beyond the preview

Go deeper on ANR.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ANR.

Explore the full profile